Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1% GPB Cream vs Qbrexza in Primary Axillary Hyperhidrosis
NCT04159610Phase 2Withdrawn
- Sponsor
- Dr. August Wolff
- Start
- Dec 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of broparestrol in primary axillary hyperhidrosis (PAH) (2 arms), sponsored by Dr. August Wolff. Primary endpoint: Measurement of the Steady State systemic Levels of glycopyrronium at Day 16. Planned start Dec 2019; status: withdrawn.
02
Drugs
broparestrol
03
Conditions
primary axillary hyperhidrosis (PAH)
Beyond the preview
Go deeper on NCT04159610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159610.